The effects o he antiviral agenlt ribavirin on reproduction and deve.Jpment have been examined by several experimental means in multiple animal species. In studies designed primarily to explore its mechanism of action1 on in utero development, the incidence, nature, and patterns of effect were directly correlated tlo embryonic gestational age at the time of maternal treatment. In a detailed evaluation of the pattern of embryonic cell death, there was a clear relationship between tissue necrosis and the types of congenital defects produced at effective doses. At subthreshold treatment levels there were no abnormalities in the young or necrotic areas in the embryoniclfetal tissues examined. When the developmental toxicity of ribavirin was examined, few if any, developmental malformations were present that could be related with confidence to the test agent. Several malformed fetuses were present in the highest dose level tested in rats (10 mglkglday) treated by gavage from Days 6-15 of pregnancy, but none were reported in rabbits similarly treated with as muchi as 1.0 mglkg per day (highest dose tested) from Days 6-18 of pregnancy. The treatment level in rats may have been associated with maternal toxicity, but this important point is not established clearly for either species. When evaluated for effects on reproduction and postnatal survival in rats, ribavirin at levels of 60 and 90 mglkglday produced statistically significantly andlor clearly dose-related increased incidences of fetal resorptions, abnormalities, and reduced postnatal survival. Pregnant baboons given ribavirin orally at submaternally toxic levels of 60 or 120 mglkg per day during critical periods of differentiation and organogenesis were reported to have produced no adverse effects on in utero development.
INTRODUCTION
RECLINICAL SAFETY EVALUATIONS OF PHARMACEUTICALS consist of a series of studies in experimental animals P by protocols that are similar throughout the developed world. The tests for reproductive and developmental toxicity involve some of the more coimplex evaluations made. When the National Academy of Sciences surveyed the universe of chemicals presently in use, laboratory tests for reproductive and developmental effects were the classes of evaluation most frequently absent from chemical databases and, even when such studies were made, they frequently were inadequate in either design, execution, or reporting. In \iew of the unique vulnerability of the embryo to some chemicals and its limited, even though impressive, repair capacity after exposure to others, it is particularly important for preclinical developmental toxicity studies to be conducted in a manner consistent with the standard protocols and for the data to be interpreted carefully. The interpretation of developmental toxicity data has Department of Anatomy. Jefferson Medical College. Thomas Jefferson Univerait! . Philadelphia, Pennsylvania JOHNSON a special importance because unsubstantiated conclusions or uncritically analyzed data can lead to alarms that may precipitate considerations of elective abortion for trivial exposures to nondevelopmentally targeted chemicals and thus be more dangerous than the exposures themselves. Awareness that at sufficiently high exposure or treatment levels, etc., most agents are capable of interfering with in utero development") is, perhaps, the initial caution in interpretation of laboratory animal developmental toxicity data.
THE NATURE OF RIBAVIRIN AND EARLY MECHANISTIC TESTS
Ribavirin is a potent inhibitor of inosine monophosphate dehydrogenase with activity against a spectrum of DNA and RNA viruses. Based on this biochemical mechanism of action, it is logical to consider that ribavirin would produce a spectrum of adverse effects on in utero development. This probability was examined in pregnant hamsters.(*) In this study, 22 hamsters were treated i.p. on Day 8 of pregnancy with ribavirin, 1.25 to 6.25 mg/kg maternal body weight. With increasing dosage, the number of normal fetuses declined, while the number with abnormalities as well as the number of resorptions increased in a dose-related manner. The defects involved several organ systems including the eye, central nervous system, limbs, and axial skeleton. In a more comprehensive follow-up report,(3) the effects of this synthetic nucleoside in both rats and hamsters treated by oral, intraperitoneal, or intravenous routes were examined and reported after maternal treatment by each route of exposure. The more extensive experiments were made using the intraperitoneal route of treatment, and in these fetuses the classic pattern of effects expected from nucleic acid inhibitors was demonstrated. That is, there was a changing pattern of developmental effects when treatment occurred at different times during gestation, and there was a reduction in the severity of the effects when treatment occurred later rather than earlier in gestation. In this study, groups of pregnant hamsters were treated i.p. with ribavirin 5 mg/kg maternal body weight on either Day 7 , 7 1/2,8,8 1/2, or 9 of gestation.
Consistent with chemicals considered to have similar mechanisms of action in the e m b r y~, (~,~) maternal treatment during the earlier days of gestation resulted primarily in defects of brain and eye; treatments begun slightly later produced many defects of upper and lower limbs, and those fetuses from mothers treated still later in pregnancy had a preponderance of their malformations of the lower limb. In other words, the timing of treatment markedly influenced the nature of the congenital malformations present at term and did so in a manner exactly consistent with the sequence for appearance of the anlagen of each of the organs. Early treatment resulted in malformations of those structures that begin to develop early. Slightly later treatment produced malformations, not in these organs (or, if so, at a much lower rate in these organs), but instead in organs developing somewhat later during pregnancy. These basic patterns of effect type and developmental stage at treatment also were observed in similarly treated rats, but in a less obvious manner due to the more restricted doses and timing of treatment (Day 9 only) examined.
As useful as these early studies were, they were performed at a time when it was considered relevant simply to produce congenital malformations by short-term pulse-type experiments employing very high dosage levels. Such an experimental protocol is markedly more efficient for producing congenitally malformed fetuses than is the more prolonged exposure period practiced currently;'6) however, it leaves several highly relevant questions unanswered. Studies of this type do not provide several items essential for a more comprehensive evaluation of a chemical's developmental toxicity hazard potential. The no observed adverse effect level (NOAEL) for developmental toxicity was not demonstrated and, although the investigators state that there were no apparent effects on maternal homeostasis due to the drug treatment, the reports contain no useful data regarding maternal status.
Another study'') further examined the effects of ribavirin on embryonic development in mice. In this report, mice were treated with single i.v. doses of ribavirin on Days 10 to 13 of gestation, and the pattern of developmental effects was related to the time of administration during pregnancy that treatment of the mothers occurred. The experiment was designed to explore the mechanisms of ribavirin action on embryos and, perhaps because treatment began somewhat later in gestation than it did in the preceding studies, fewer malformations were produced. Nevertheless, the data illustrated that increasingly larger doses were needed to produce developmental effects at a later gestational stage than were necessary at earlier and more susceptible stages of differentiation and organogenesis. The NOAEL for developmental toxicity was 10 mgikg when treatment occurred on Day 10 and was either at, or very near to, 100 mg/kg when treatment was delayed until Day 12 or 12.5. Furthermore, in every EFFECTS O F RlBAVIRlN instance where the data are adequate for an interpretation, the percent of fetuses with malformations was directly proportional to the fetal weight reduction. There were instances where dose levels that caused marked reduction in fetal weight did not result in observed congenital malformations, but at increasingly higher doses administered on the same gestational day, there was a clear pattern of increasingly severe adverse effect on fetal weight and a concomitant increase in the malformation frequency among the live fetuses. Treatment with 100-1 75 mgikg on Day 11 or 1 1.5 produced the broadest spectrum of developmental effects. In several groups of pregnancies treated during this period, there was as much as a 40% fetal weight reduction and 100% of the surviving offspring were malformed. These treatment levels were severely toxic to the embryos, as was indicated by a 50% reduction in ['Hlthymidine uptake and DNA content. In a detailed histologic evaluation of the embryonic limbs, widespread mesenchymal cell death was present in embryos exposed early in development, but after treatment later in gestation, the necrotic areas were more localized within the distal limb areas. At a dose of 25 mgikg. no apparent cell damage was produced and there were no limb defects present at term. Similar to the preceding studies, this study provided valuable information regarding several mechanistic aspects of ribavirin effects on development. It was not designed as a safety evaluation, however, and did not provide infonation regarding maternal status during or immediately after treatment. From these data, one cannot evaluate the real potential of ribavirin to produce human congenital malformations at relevant exposure levels. Not the least of the problems would be that it is difficult to extrapolate the effects of exposure routes used in these animal studies to the most likely route of human exposure, or the intensity of exposure and its effects on the mothers to the effect level in the concepti.
The preceding mechanistic studies established that ribavirin shared with most chemicals in commerce an ability to interfere with in utero development when treatment occurred at sufficiently high levels.'8' Each study had used very short and very intense treatment, with the drug injected directly into the pregnant mothers. In mechanistic studies, an effort is made to produce as high a percentage of abnormal offspring as possible in order to increase the efficiency of animal usage and evaluation as well as to fully demonstrate the types of effects that a chemical can cause.
OVERVIEW OF REPRODUCTIVE AND DEVELOPMENTAL TOXICITY TESTING
For developmental toxicity, as in all other types of toxicologic effects where a threshold phenomenon is assumed to be operative, safety evaluations are based on the no observed adverse effect level determined in very carefully designed safety evaluation studies conducted in relevant animal species. The NOAEL of the most sensitive species is taken as the starting point for cross-species extrapolation to the human and an exposure level that is believed unlikely to cause human developmental toxicity is calculated from this point."' Human exposure is generally assumed to be permissible at a level of 1/100 the NOAEL in a relevant animal species, but this safety factor or, by a slightly different calculation, margin of safety may be somewhat smaller provided there is a pharmacobiologic reason for considering that the animal would be more sensitive than the human. Conversely, if there is a basis for greater uncertainty, it can also be larger than lil00 the animal NOAEL if the study, for instance, employed only small groups of animals or did not entail fully appropriate means for evaluating the fetuses. A margin of safety larger than 100 could be prudent if human exposure was to be chronic and if there was a propensity for the chemical to accumulate in body tissues. Instances such as these might necessitate a larger margin of safety if such were to be based solely on the shorter treatment period of the usual developmental toxicity safety evaluation testing protocol. For such agents where chronic human exposure is probable. there are alternate safety evaluation tests that take this factor into account with the goal of achieving a NOAEL determination in the experimental animals more relevant than that provided by the niore common developmental toxicity testing method.
In view of the potential for ribavirin exposure to women of child-bearing potential, comprehensive studies of ribavirin relevant to safety assessment were conducted during the early 1970s. These tests were of several types. Table 1 depicts the more common and standard developmental and reproductive toxicity tests with which an evaluation of a pharmacologic chemical usually begins.
The standard developmental toxicity testing protocol is the Segment 11 evaluation.' '"I In this type study. the male animals are not treated at all and the females do not begin treatment until. or just after, the time that the blastocyst begins implantation into the uterine lining. Treatment continues throughout the period of most rapid embryonic differentiation and organogenesis, and ends at the beginning of the fetal stages of in utero life. In other words, from JOHNSON Treatment of lactating mothers through we an i n g aThe timing provided is for rats. That for other species differs from this. bUsually a sham-treated control group and three agent-treated groups are used. The dose levels are chosen with the goal of producing no maternal or developmental effects in the low-dose group and at least maternal toxicity in the high-dose group (no more than 10% maternal death).
CThe IBT rabbit developmental toxicity study added at C-section, the young were placed in a 37°C incubator and tested for respiratory and paw movements hourly for 7 h, and at 24 h for viability.
EFFECTS OF RIBAVIRIN
the point of view of the embryo, this is a whole life exposure. Treatment of the mothers begins as the first germ layers of the embryo are formed and ends sometime after embryogenesis has been completed and the fetal stages of more physiological maturation are occurring.
The Segment I type experiment''') is usually executed in rats and is a test of a chemical's ability to interfere with factors related to reproductive performance, including gamete formation. the fertilization process, parturition, lactation. nurture, and postnatal well-being. In this protocol, the males begin treatment before mating occurs, and the duration of their treatment is sufficient so that all of the spermatozoa that are used in the eventual inseminations were produced while the chemical was present in the males' body. The treatment period for the females usually occurs for a shorter period prior to mating, but never for less than two weeks prior to cohabitation. The test agent also is administered throughout pregnancy. delivery of the offspring, and until the young are weaned. Exposure after delivery provides an 0pportunit.y to evaluate the effects of the test chemical on the offspring and maternal nurture. Table I outlines the periods of exposure used for standard developmental and reproductive toxicity tests in rats which are a portion of the safety (evaluation for drugs.
REPRODUCTIVE AND DEVELOPMENTAL TOXICITY EYALUATIONS OF RIBAVIRIN
Ribavirin was tested for developmental toxicity in both pregnant rats and rabbits.' I . I 2 ) The salient data from the study in Charles River rats are presented in Table 2 . In this Segment I1 type developmental toxicity study, pregnant rats were treated by oral gavage with ribavirin (in distilled water) 0, 0.1, 1.0, or 10 mgikg maternal body weightlday beginning on Day 6 and ending on Day 15 of gestation. Day zero of gestation was considered to be the day sperm were found in the vagina, and on Day I the inseminated and presumed pregnant females were shipped to the testing laboratory. Feed and aater were provided ad libitum. and the females were terminated by carbon dioxide asphyxiation on Day 20. Clinical signs or cage-side observations of maternal condition during or after treatment were made, however, even though it was stated that none were observed. the methods of ascertainment were not explained and no actual data were reported. At autopsy, the corpora lutea and implantations were counted, aPrimarily supernumerary or structurally atypical ribs and delayed sternal ossification. bAll were either large or small atria.
remainder were primarily either large or small atria.
1 .I% Anopthalmia, 6.7% hydrocephalus, 1 . 1 % gastroschisis 1 . 1 % renal ectopia, 2.3% undescended testis; the JOHNSON the fetuses removed, blotted dry and weighed, subjected to external inspection, and approximately half of each litter was examined by free-hand razor blade cross sections and the other half for skeletal osseous status after alizarin staining. No statistical analysis was reported for any maternal or fetal parameter. No maternal or fetal parameter was reported to show any clearly dose-related effect of treatment at any of the dosage levels used. Maternal weight gain was not markedly affected in even the high-dose rats early in treatment or when measured throughout and over the entire treatment period, or thereafter. Maternal weight gain during the Days 6 through 15 treatment period was less in the 10 mg/kg per day group than in any other group. In the absence of statistical analysis and historic control data from the laboratory, it is difficult to attribute this fully to the test agent.(I3) Similarly, at this dose level, resorptions were more frequent than in the controls, and both male and female fetal weights were less than controls. The percent grossly abnormal fetuses and the incidence of skeletal or soft tissue malformations were somewhat greater than in the controls but, as was the case for possible maternal effect in the high-dose group, these observations are difficult to attribute with confidence to the test agent. In the fetuses subjected to free-hand razor blade cross-sectioning, the malformations in the controls, 0.1, and 1 .O mg/kg groups were all reported as either atypically large or small atria, whereas those in the high-dose group included incidences of anopthalmia, hydrocephalus, and gastroschisis. From this study one cannot conclude that there is an effect of the agent on either mother or fetus. However, one must allow at least the possibility that the maternal weight gain and fetal parameters that were different from controls could well be the low end of a dose-response relationship. This possibility is consistent with the difference in the pattern of malformations in the high-dose group, in contrast to the difficult to interpret and even somewhat implausible large or small atria findings reported in the other three groups. The type malformations one would expect to find from a nucleoside, and consistent with the classes of malformations found in other studies, were reported only in the high-dose group treated with 10 mg/kg per day. If this exposure level is considered as at least a minimal effect level, this observation would be consistent also with the small for gestational age male and female fetuses in this dosage group.
The effects of ribavirin on embryonic development also were examined in a standard Segment I1 test using New Zealand White rabbits.'") Ribavirin was administered in gelatin capsules on Days 6 through 18 of pregnancy at levels 0,O. 1,0.3, and 1 mglkg per day (Table 3 ). Day zero of pregnancy was considered as the day of artificial insemination of hormonally primed females with diluted pooled semen from proven bucks. The animals were individually housed, and feed and water were provided ad libitum. Cageside observations of clinical signs of treatment were made but not reported. On Day 29 of pregnancy, the females were sacrificed, the young removed by caesarian section, cleaned of membranes, examined externally, and placed into a 37°C incubator for hourly assessment of respiratory and paw movements for 7 hours and then again at 24 hours of incubation for viability. All young were examined by dissection and then prepared and stained with alizarin"4' for assessment of skeletal osseous status. There were 10, 1 1, 12, and 13 pregnant does with implantations at Day 29 autopsy in the control, low-, mid-, and high-dose groups, respectively. An increased incidence of early and late resorptions were reported in the high-dose group, but these were stated to be within the historic range for the laboratory and many occurred in only one litter. No decrement of anticipated normal maternal weight gain was reported in these animals during treatment, and the postdosing weights of the high-dose females was not greater than the controls. It should be noted, however, that the amount of test agent given to these animals was the smallest of any of the Industrial Bio-Test (IBT) studies. One would assume that at a higher dosage, adverse effects on maternal homeostasis would be observed. Even in rabbits, where maternal weight gain during pregnancy is highly variable, one can sometimes detect a weight gain rebound-type phenomenon in the postdosing period when there is only a slight decrement of anticipated maternal gain during dosing. However, the data in this report are not adequate, namely, do not provide shorter, 3 or 4 day, weight chat& data immediately after treatment cessation, so one cannot be certain on this point in these pregnant rabbits. No gross structural malformations were reported in any group and no dose-related effects on skeletal status of the pups or their viability was relatable to the test agent. Most significant is the fact that mean pup weight was essentially identical between the high-dose and the control groups. If, indeed, a nucleoside were present in these animals at a level sufficiently high to cause early and late resorptions, then one would anticipate there to be an adverse effect on mean pup weight and skeletal maturational status. This did not take place in this study, and in fact there was no pattern of any type malformation.
The effect of ribavirin on reproduction was evaluated in a Segment I type study in rats ( Table 4 ) tested at very high exposure levels. In this study'") ribavirin was given to Charles River rats by gavage in distilled water at levels of 0, 30, 60, and 90 mg/kg per day. Treatment of the males began at 40 days of age and continued through the agecause this laboratory was found to have reported suspect data on occasion, this reviewer made special efforts to examine for and detect internal inconsistencies in the data. Allowing for the fact that the studies of IBT reviewed were made before the presently operative Good Laboratory Practice procedures and guidelines for quality assurance were developed, no factor was found that was considered to prevent evaluation of the data. Whereas several reporting ambiguities were found and statistical analysis was largely absent, the uniformity of these groups weights was the most "suspicious" data detected. gExcluding one female whose entire litter was resorbed. hExcluding two females whose entire litters were resorbed 'Interpreted by the reviewer to include incidence at term plus those observed during lactation and at weaning examination. The methods of examination were not explained in the report. The more prevalent abnormalities reported were: excencephaly, agnathia, cleft lip. No pattern of effect was detectable among the groups. 'The reported numbers of fetuses and percent malformed were unreconcilable by this reviewer. kAccording to preceding data, eight females in this group delivered. 'Statistically significantly different from controls (95% confidence level).
breeding period, which apparently began when they were 100 days old. Dosing of the females began at 86 days of age (i.e., 2 weeks prior to breeding). They were caged in pairs with as many as three males sequentially in a series of 10 day exposures. Day zero of pregnancy was the day on which spermatozoa were observed in the vaginal contents. Feed and water were available ad libitum. Half of the females in each group were sacrificed on Day 14 of pregnancy for inspection of the reproductive tract and recording of the corpora lutea, implantation sites, and live and resorbing products of conception. The remaining half of each group of pregnant females delivered naturally and remained with their young through weaning. The pups were examined for external abnormalities at birth and at Day 21 weaning. In this study there was no statistically significant effect reported in the adult females or males. All of the reproductive indices were within normal limits and no dose-response relationship was evident for any parameter. However, the number of resorptions was elevated in at least the high-dose group and the number of viable fetuses at Day 14 interim sacrifice was lower than that of the controls. The number of viable pups delivered was statistically significantly reduced in the high-dost group. Postnatal pup survival also was reduced in this group at lactation Days 1 and 21 with the disrinct probability of a dose-response effect on this parameter in the mid-dose group as well. The incidence of "abnormal" progeny was greater in all the treated groups than in the concurrent controls. No historic data from this laboratory are available for review, however, one could rely on experience and consider that the total absence of any "abnormalities" in the controls is unusual. Clearly, there is reason to hold that a dose-response relationship of effect exists for the mid-and high-dose groups. That is, the increased incidence of resorptions and early pup deaths could have included an incidence of malfornied fetuses and pups, particularly when it is not clear from the report exactly which animals are included and the method of examination is not clearly stated.
These data do not fit any obvious pattern of effects and are difficult to interpret, particularly, in view of the fact, that in the rat Segment I1 study (Table 12 ) weight gain was altered by 10 mgikg per day, but in this Segment I study, even 90 mgikg per day did not produce an obvious effect on body weight. The absence of effect on fetal weight i s interesting in conjunction with a dose-response curve of increased resorptions, and a decreased number of viable fetuses at term and at lactation Day 2 I , and an obviously dose-related incidence of malformed offspring, at least in the mid-and high-dose groups. It would appear from these data that the developmental and postnatal survival NOAEL is probably 30 mgikg. In this reviewer's opinion this is the developmental NOAEL, as supported by the fact that two of the three "abnormal" fiztuses reported had talipes-an effect often more relatable to postmoribund changes than actual bony abnormality. The third abnormality was gastroschisis, a relatively common finding in untreated rats. The adult male and feniale NOAEL is greater than 90 mgikg per day. The effects of ribavirin on in utero idevelopment were examined in a preliminary or pilot study using pregnant baboons."6) This is a limited study with but one female per "group." They were fed bananas containing a corn oil suspension of ribavirin at nonmaternally toxic dose levels of 60 or 120 mgikg per day during various gestational periods ( Table 5 ). The females were inidividually housed and inspected daily for reaction to the test compound. At Each fetus was dissected and then skinned for alizarin staining of ossified skeletal components. In this study, no maternal weight gain data during treatment were provided, and no signs of drug effect were detected in the young.
CONCLUSIONS
Ribavirin interferes with cell replication and, similar to other agents of this type, produces adverse effects on in utero development, provided the exposure level is sufficiently intense. The presently available data are consistent with the view that ribavirin has no selective developmental toxicity or propensity to disrupt development at dose levels lower than levels that adversely effect maternal homeostasis. However, exact documentation of this relationship is unclear from the available data and must await more state-of-the-art studies. The reports of mechanistic evaluations focus exclusively on the concepti and the more standard safety evaluation type studies were made in the early 1970s before present-day tests were available to support such determinations.
The early studies employed intravenous or intraperitoneal treatment routes on only a few or even single gestational days and are largely irrelevant for safety evaluation and regulatory purposes. The developmental toxicity NOAEL was between 1 and 10 mgkg per day in orally treated rats based on frank gross structural malformations, and greater than 1 .O mg/kg per day in rabbits. Reproductive toxicity in rats, manifested as effects on postnatal survival, occurred at a statistically significant incidence in the 90 mg/kg per day group. In the group receiving 60 mg/kg per day there also was a dose-relatable, though not statistically significant, effect in these parameters and, therefore, 30 mgikg per day is considered as the reproductive NOAEL from these data. The greater than 120 mg/kg per day NOAEL reported in pregnant baboons is interesting, even though this was a pilot-type study. It may be that this closer relative of the human is markedly less sensitive than rats and rabbits. The exact basis for this apparent large interspecies difference is not available from the studies and dose levels examined to date, therefore, the margin of safety is best derived from the rat and rabbit reproductive toxicity NOAEL of at least 1 mg/kg per day via oral ingestion. The NOAEL via inhalation is not established by the studies available.
It is this reviewer's opinion that the IBT studies were designed, conducted, and reported in a manner generally consistent with their contemporaries, and no actual basis for questioning the data was detected. If anything, perhaps higher NOAELs would be established by more current evaluations. One cannot predict this accurately because the details of malformation type attributable to individual females and their respective homeostatic status during the studies was not reported.
